Vifor

After delay, CSL's $11.7B deal for Vifor poised to close next week
Fierce Pharma
Tue, 08/2/22 - 10:39 am
M&A
CSL
Vifor
antitrust
Akebia scrapes together $85M war chest to commercialize vada as PDUFA date looms
Endpoints
Thu, 02/24/22 - 09:30 am
Akebia
Vifor
anemia
vadadustat
The top 10 biopharma M&A deals in 2021
Fierce Pharma
Tue, 01/18/22 - 10:53 am
M&A
CSL
Vifor
Jazz Pharmaeuticals
GW Pharma
Novo Nordisk
Dicerna
Horizon Therapeutics
Viela Bio
Perrigo
HRA Pharma
Sanofi
Kadmon
Merck
Acceleron
Pfizer
Arena Pharmaceuticals
Translate Bio
Trillium Therapeutics
Amgen
Five Prime Therapeutics
With approval in sight, Vifor expands deal for partner's anti-itch drug
BioPharma Dive
Tue, 10/20/20 - 09:58 pm
Cara Therapeutics
Vifor
dialysis
chronic kidney disease
Vifor buys priority review voucher for undisclosed filing
Fierce Biotech
Tue, 02/18/20 - 10:28 am
Vifor
priority review vouchers
FDA
priority review
J&J taps kidney specialist Vifor for Invokana marketing help
Fierce Pharma
Mon, 11/4/19 - 07:16 pm
JNJ
Invokana
Vifor
drug reps
nephrologists
Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study
Pharmaceutical Business Review
Mon, 05/13/19 - 09:25 am
Vifor
hypertension
chronic kidney disease
Veltassa
clinical trials
AstraZeneca potassium drug finally approved, threatening Vifor
Yahoo/Reuters
Mon, 05/21/18 - 09:01 am
AstraZeneca
Lokelma
hyperkalemia
ZS-9
Vifor
Valtessa
FDA